TD Cowen maintains Hold rating on UnitedHealth stock

Following UnitedHealth's annual shareholder meeting, TD Cowen maintained its Hold rating with a $308 price target despite a nearly 50% share decline over six months; new CEO Stephen Hemsley emphasized pricing discipline, particularly for 2026 Medicare Advantage bids, and a comprehensive review of risk assessment coding. Analysts at KeyBanc, JPMorgan, Wolfe Research, and Bernstein SocGen Group have varying outlooks, with price targets ranging from $377 to $405, reflecting differing views on Medicare Advantage margins and Optum Health's growth potential, while director Andrew Witty's resignation adds to the uncertainty.

Analysis

UnitedHealth Group (UNH), valued at $274 billion, presented a cautiously optimistic outlook at its recent annual shareholder meeting, despite its shares declining nearly 50% over the past six months. The new CEO, Stephen Hemsley, who succeeded Andrew Witty on May 13, emphasized key strategic priorities including disciplined pricing for the 2026 Medicare Advantage bids, reflecting elevated care activity, and a comprehensive review of risk assessment coding practices with independent expert involvement. The company plans to provide a cautious outlook for 2025 and initial perspectives for 2026 in its Q2 earnings report on July 29. While TD Cowen maintained a Hold rating and a $308 price target, InvestingPro analysis suggests the stock, trading at a P/E ratio of 12.6, is undervalued. Other analysts offer varied perspectives: KeyBanc lowered its target to $400 (from $450) but kept an Overweight rating, viewing current valuations as overly pessimistic on Medicare Advantage margins. JPMorgan reiterated an Overweight rating with a $405 target, confident in UNH's ability to manage complexities. Wolfe Research maintained Outperform ($390 target), forecasting potential EPS of $21-$22 by 2025, and Bernstein SocGen Group reaffirmed Outperform ($377 target), highlighting Optum Health's projected 8% CAGR. Uncertainty lingers due to undisclosed government investigations and the recent unexplained resignation of director Andrew Witty. Hemsley also clarified that AI is utilized for administrative burden reduction, not for influencing medical practice decisions.

Key Decisions for Investors

• Given the significant share price decline and a P/E ratio of 12.6 suggesting potential undervaluation, investors should evaluate the opportunity against the company's cautious 2025 outlook and the ongoing comprehensive review of risk assessment coding.
• It is crucial to monitor UnitedHealth's Q2 earnings release on July 29 for detailed 2025 guidance, initial 2026 outlook, and specific impacts of the new pricing discipline, particularly concerning Medicare Advantage bids and commercial strategies.
• Investors should consider the mix of analyst ratings, ranging from Hold to Overweight with price targets between $308 and $405, alongside the ongoing management transition and undisclosed government investigations, when assessing risk and potential adjustments to their UNH positions.